

REMARKS

A. Status of the Claims

The pending claims have been canceled and rewritten as new claims 62-90. This was done primarily to rearrange claims in a more proper order. New claim 62 corresponds essentially to previous claim 14, with some amendment. New claim 62 references obtaining a peptide that is already attached or fused to an agent to be delivered to a prostate cancer (as opposed to "attaching" the agent to the peptide). This was done in that the previous claim 14 could have been construed as not covering fusion peptides (*i.e.*, where the agent is a peptide that is fused to the targeting peptide by means of fusion of DNA coding sequences). Support for amended claim 62 can be found in original claim 14 (as amended). Thus, to further clarify this possibly, new claim 62 includes the language "or fused" to an agent. Support for fusion proteins can be found, for example, on pages 35-36 of the specification. Support for new claims 86-91 can be found in original claims 24, 29, 31, 44-46 and the examples.

As can be seen, Applicants have taken the liberty to re-introduce the subject matter of previously withdrawn claims in anticipation of the withdrawal of the pending rejections of the previously pending and examined claims in view of the telephonic interview held on December 17, 2008.

B. Anticipation

Various of the previously pending claims were rejected as anticipated by Arap *et al.*, WO/2002/020723. As noted in the telephonic interview, Arap *et al.* has not been shown to be prior art to the present claims.

D. Obviousness


Various of the previously pending claims were rejected as obvious over Thakur *et al.* in view of Ellerby *et al.*, Campbell *et al.* and Schally *et al.* In response, Applicants continue to observe that

none of these references teach prostate targeting, nor do they teach or suggest a prostate targeting sequence. Nonetheless, as discussed in the aforementioned telephonic interview, Applicants have cancelled claim 1 and claims depending solely therefrom, and amended the claims accordingly to depend solely from claim 14 (now claim 62), such that the present rejection has been overcome.

Additionally, the obviousness rejections over Arap *et al.* are overcome for the reasons discussed above.

E. Conclusion

It is submitted that the present claims are in condition for allowance. The Examiner is invited to contact the undersigned attorney at (512) 536-3055 with any questions, comments or suggestions relating to the referenced patent application.


Respectfully submitted,

David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)
Date: January 29, 2009